Lyka Labs Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹109.4
- Today's High:
- ₹115.25
- Open Price:
- ₹111.6
- 52W Low:
- ₹89
- 52W High:
- ₹155.65
- Prev. Close:
- ₹113.85
- Volume:
- 16002
Company Statistics
- Market Cap.:
- ₹3.92 billion
- Book Value:
- 14.806
- Revenue TTM:
- ₹848.02 million
- Operating Margin TTM:
- -0.93%
- Gross Profit TTM:
- ₹555.18 million
- Profit Margin:
- -18.46%
- Return on Assets TTM:
- 1.02%
- Return on Equity TTM:
- -44.46%
Company Profile
Lyka Labs Limited had its IPO on under the ticker symbol LYKALABS.
The company operates in the Healthcare sector and Biotechnology industry. Lyka Labs Limited has a staff strength of 296 employees.
Stock update
Shares of Lyka Labs Limited opened at ₹111.6 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹109.4 - ₹115.25, and closed at ₹110.65.
This is a -2.81% slip from the previous day's closing price.
A total volume of 16,002 shares were traded at the close of the day’s session.
In the last one week, shares of Lyka Labs Limited have slipped by -5.1%.
Lyka Labs Limited's Key Ratios
Lyka Labs Limited has a market cap of ₹3.92 billion, indicating a price to book ratio of 28.3466 and a price to sales ratio of 3.3748.
In the last 12-months Lyka Labs Limited’s revenue was ₹848.02 million with a gross profit of ₹555.18 million and an EBITDA of ₹100.36 million. The EBITDA ratio measures Lyka Labs Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Lyka Labs Limited’s operating margin was -0.93% while its return on assets stood at 1.02% with a return of equity of -44.46%.
In Q2, Lyka Labs Limited’s quarterly earnings growth was a positive 0% while revenue growth was a negative 16.8%.
Lyka Labs Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at ₹-5.59 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lyka Labs Limited’s profitability.
Lyka Labs Limited stock is trading at a EV to sales ratio of 4.3477 and a EV to EBITDA ratio of 13.2389. Its price to sales ratio in the trailing 12-months stood at 3.3748.
Lyka Labs Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹1.52 billion
- Total Liabilities
- ₹325.98 million
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
Lyka Labs Limited ended 2025 with ₹1.52 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹1.52 billion while shareholder equity stood at ₹454.41 million.
Lyka Labs Limited ended 2025 with ₹0 in deferred long-term liabilities, ₹325.98 million in other current liabilities, in common stock, ₹-1356577000.00 in retained earnings and ₹2.21 million in goodwill. Its cash balance stood at ₹117.11 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹637.89 million.
Lyka Labs Limited’s total current assets stands at ₹442.04 million while long-term investments were ₹0 and short-term investments were ₹25.59 million. Its net receivables were ₹201.26 million compared to accounts payable of ₹94.06 million and inventory worth ₹69.54 million.
In 2025, Lyka Labs Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Lyka Labs Limited paid ₹0 in dividends in 2025.
Other key metrics
- Current Trading Price
- ₹110.65
- 52-Week High
- ₹155.65
- 52-Week Low
- ₹89
- Analyst Target Price
- ₹
Lyka Labs Limited stock is currently trading at ₹110.65 per share. It touched a 52-week high of ₹155.65 and a 52-week low of ₹155.65. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹112.73 and 200-day moving average was ₹116.08 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 4886.1% of the company’s stock are held by insiders while 267.9% are held by institutions.
Frequently Asked Questions About Lyka Labs Limited
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia. The company offers its products in various forms, including injections, creams, ointments, foams, gels, and lotions. It also exports its products. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India.